Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26738562 | 1.00 | KDM1A (0.33) | KDM1AACHEHTT | |
| SCHEMBL4775672 | 1.00 | KDM1A (0.33) | KDM1AACHEHTT | |
| SCHEMBL347164 | 0.82 | — | — | |
| SCHEMBL474897 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL347994 | 0.80 | ACHE (0.34) | ACHE | |
| Hydrochloric Acid SCHEMBL21243978 | 0.80 | ACHE (0.34) | ACHE | |
| Hydrochloric Acid SCHEMBL347993 | 0.80 | ACHE (0.34) | ACHE | |
| Hydrochloric Acid SCHEMBL475087 | 0.80 | ACHE (0.34) | ACHE | |
| Hydrochloric Acid SCHEMBL346915 | 0.80 | ACHE (0.34) | ACHE | |
| SCHEMBL15450836 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220298110-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2022-09-22 | — | — | US | disclosed |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | KDM1A 1269/4885ACHE 1584/4885HTT 2253/4885 |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-20220298110-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | KDM1A 1269/4885ACHE 1584/4885HTT 2253/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | KDM1A 1269/4885ACHE 1584/4885HTT 2253/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | KDM1A 3336/4885ACHE 4608/4885HTT 2894/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885ACHE 2683/4885HTT 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.